

UNITED STATES DISTRICT COURT
DISTRICT OF NEW JERSEY

**IN RE: VALSARTAN LOSARTAN &
IRBESARTAN PRODUCTS LIABILITY
LITIGATION**

This Document Relates to All Actions

MDL No. 2875

Case No. 1:19-md-02875-RBK-JS

Honorable Robert B. Kugler,
District Court Judge

Honorable Karen M. Williams,
Magistrate Judge

NOTICE OF APPEARANCE

To the Clerk:

Please enter the appearance of Kathleen E. Kelly hereby in this MDL on behalf of Defendant Sciegen Pharmaceuticals Inc. on this Court's MDL master docket, and requests to be added to the CM/ECF system list in this matter at the following email address: kekelly@hinshawlaw.com. I have been admitted *pro hac vice* in this Court for this matter pursuant to MDL Case Management Order No. 1.

By entering an appearance, the undersigned Defendant does not waive any defenses, and specifically preserves all defenses related to service and personal jurisdiction in any individual case that is currently pending in MDL 2875 or that subsequently may be transferred to or consolidated with MDL 2875.

Dated: July 29, 2021

Respectfully submitted,

/s/ Kathleen E. Kelly

Kathleen E. Kelly

HINSHAW & CULBERTSON, LLP

53 State Street, 27th Floor

Boston, MA 02109

617-213-7000; 617-213-7001 fax

kekelly@hinshawlaw.com

Attorneys for Defendant

Sciegen Pharmaceuticals Inc.

CERTIFICATE OF SERVICE

I, Kathleen E. Kelly, hereby certify that on July 29, 2021, the foregoing **Notice of Appearance** was filed through the ECF system and will be transmitted electronically to the registered participants as identified on the Notice of Electronic Filing (NEF).

/s/ Kathleen E. Kelly

Kathleen E. Kelly